Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Formulary Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy AMB25-AHS-C-00023-GA

    Ambetter Formulary (Prescription Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for Centene Policy AMB25-AHS-C-00023-GA alerts

    Get alerted when Policy AMB25-AHS-C-00023-GA changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Ambetter prescription drug formulary, tiering, prior authorization, quantity limits, step therapy, specialty pharmacy requirements, and opioid prescribing limits for members covered under the plan.

    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-GA
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionComplete and submit the Prior Authorization form with required documentation for any drug marked PA to avoid denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0-4Formulary copay tiers described
    7-dayOpioid new-start limits
    QL/PAQL / PA frequent
    Jan 2026Formulary version
    SP requiredSpecialty fill requirement

    Formulary Coverage & Conditions

    Formulary coverage

    Formulary coverage principles

    Formulary coverage rules: Drugs listed on the formulary are FDA‑approved medications covered under the prescription drug benefit; generics are considered first‑line when available. The formulary is not a complete list of covered drugs — not all dosage forms or strengths may be covered and plan benefit designs may impose additional limitations.

    Check member benefit for plan‑specific coverage and cost share.

    Non-Formulary Drug PA

    Prior authorization for non-formulary drugs

    PA requirement: Prior authorization is required for non‑formulary drugs; the provider must submit the Prior Authorization form and supporting information. Urgent requests will be responded to within 24 hours and non‑urgent within 72 hours (unless state law requires a faster response).

    Denial notices will state specific reasons or identify missing information.

    Policy Summary
    PayerCentene
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-GA
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionComplete and submit the Prior Authorization form with required documentation for any drug marked PA to avoid denial.
    SourceLink
    On This Page
    Formulary Coverage & ConditionsCodes, Quantity Limits & ExamplesAuthorization, Documentation & Risk of DenialNew-Start & Initial Therapy RequirementsStep Therapy Flags & MappingsQuantity Limits (QL) — Examples by ProductSpecialty Pharmacy, Infusion & Site RequirementsBiosimilar & Reference Product NotesAbbreviations & TermsPolicy Background & Scope

    Opioid limits

    Opioid prescribing limits for new starts

    Opioid new-start limits: New opioid prescriptions are limited to a 7‑day supply for new starts. Up to two 7‑day fills are allowed during any 28‑day period, and a maximum of 28 non‑consecutive days of supply is allowed in any 90‑day period. Fills exceeding these limits require prior authorization.7‑day supply; up to 2 fills per 28 days; up to 28 days per 90 days

    This limit applies cumulatively to all opioid medications filled.

    Product-level controls: Many opioid formulations listed include additional per‑product controls such as quantity limits (QL), tier assignment, and may require PA or specialty handling as shown on individual entries (see formulary lines for hydromorphone, methadone, enbreL, etc.).

    Apply both the new‑start rule above and the product‑specific QL/PA as listed.

    Formulary coverage entries (partial)

    Coverage entries include tier, quantity limits (QL), package/maximum fills per 180 days, age limits (AL), and PA indicators.

    Adalimumab product entries: Adalimumab reference and biosimilar presentations are listed with quantity limits and package/fill limits (e.g., QL(0.143 EA daily); package(s) per 180 day(s) retail/mail) and require prior authorization as indicated on the formulary entries.QL examples: 0.143 EA daily; package(s) per 180 days

    Multiple presentations (pens, syringes, starter kits) have specific package/180‑day limits and PA requirements.

    Actemra entries

    Tocilizumab (ACTEMRA) formulations include specific QL per period, SP/PA flags, and in one case a prerequisite trial requirement.

    ACTEMRA ACTPEN / SOLN: ACTEMRA presentations are subject to quantity limits (examples: QL(3.6 mL per 28 day(s) retail; 4 mL per 28 day(s) mail) for ACTEMRA ACTPEN) and specialty pharmacy/PA flags. For at least one ACTEMRA SOLN 200 presentation a trial of ibuprofen ('Must try ibuprofen') is noted before coverage of that formulation.QL e.g., 3.6 mL per 28 days (retail); 4 mL per 28 days (mail)

    Follow SP/PA and step requirement where indicated on the entry.

    OTEZLA entries

    PDE4 inhibitor OTEZLA has QL, PA, age limits and package limits.

    OTEZLA tablets and pack presentations list QL(2 EA daily), prior authorization (PA), and age limits (AL(At least 45 yrs old Up to 79 yrs old)). Some pack presentations additionally include package limits per 180 days and require PA.QL(2 EA daily); AL 45‑79 yrs; package(s) per 180 days

    Coverage restricted by age and PA as indicated on the formulary.

    Formulary controls (PA, QL, new-start limits, age limits)

    Coverage and utilization controls apply as follows based on formulary entries

    Default product controls: Each formulary product is assigned a tier and may include one or more utilization controls: prior authorization (PA), specialty pharmacy (SP), quantity limits (QL), new‑start supply limits (e.g., 'New starts limited to 7 day supply'), and age limits (AL). All listed controls for a product must be met for coverage of that presentation.

    Refer to individual product lines for specific QL, AL, SP, PA values.

    Formulary coverage logic (excerpt)

    Coverage and access are determined by formulary tier, quantity limits, and prior authorization where specified.

    Formulary-based coverage: Coverage depends on the formulary tier assignment (e.g., Tier 1A/1B/2/3/4); lower tiers indicate preferred status. Where QL or PA are specified, those utilization controls apply and may limit or condition coverage. This excerpt does not include diagnosis‑specific medical‑necessity criteria.

    Clinical criteria or NDC‑level medical necessity rules are not included in the provided excerpt.

    Formulary entries and utilization management

    Coverage status and utilization management indicators per drug entry

    Formulary entry requirements: Individual drugs or drug classes are assigned a tier and may include PA, SP and/or QL specifications as listed on each formulary line. When PA or SP is indicated, prior authorization or specialty pharmacy fulfillment is required for coverage as shown.

    No additional clinical inclusion/exclusion criteria are present in this segment.

    Covered with formulary conditions

    Coverage is tier-based and may require PA, SP, or have QL restrictions as listed per product.

    Covered with formulary conditions: Drugs are covered according to their assigned tier but coverage may be conditional on meeting quantity limits (QL), age limits (AL), prior authorization (PA), specialty pharmacy routing (SP), or step therapy (ST) when indicated on the formulary entry.

    Claims lacking required PA/SP or exceeding QL/AL may be denied.

    Formulary coverage conditions

    Coverage details per formulary entry — coverage depends on tier, age limits, quantity limits, and utilization management tags.

    Topical/formulation-specific conditions: Topical products are assigned tiers and commonly include age limits (e.g., AL(At least 12 yrs old)), quantity limits (QL expressed in grams or mL), and may require prior authorization (PA) or step therapy (ST) for certain formulations (examples: clindamycin phosphate topical entries, clindamycin–benzoyl peroxide combinations).

    Follow the entry‑level AL/QL/PA/ST values for adjudication.

    Formulary coverage entries (per-drug basis)

    Coverage/tiering and limits applied per listed topical and outpatient drug entries

    Per‑drug formulary node: Each drug entry shows a Tier assignment and may include Quantity Limits (QL), Prior Authorization (PA), Age Limits (AL), and preferred mapping ('prug Name'). Coverage for a specific formulation requires compliance with the listed tier and any QL/PA/AL/ST tags on that line.

    See the individual product entries (chunks referenced) for the exact QL/AL/PA values and any package/180‑day fill limits.

    The formulary is a guide to FDA‑approved brand and generic medications covered under the prescription drug benefit. Please note the formulary is not a complete list of covered drugs: not all dosage forms or strengths may be covered, and the list is periodically updated. Coverage also depends on individual benefit plan design, which may impose additional limits or exclude certain products despite appearance on the formulary; verify member benefits for coverage limitations and cost‑sharing.

    Within the provided excerpt there are no explicit exclusion statements describing products or categories that are categorically not covered.

    This segment does not include any explicit clinical exclusion criteria (for example, diagnosis‑based or contraindication‑based exclusions) for coverage decisions.

    No explicit clinical exclusion rules are stated in the excerpted formulary lines shown here; entries include tiers, quantity limits, and utilization controls but not diagnosis‑specific exclusion criteria.

    In this document segment there are no explicit exclusion conditions listed that would universally deny coverage for a drug or class.

    Across the supplied excerpts there are no statements labelling items as “not medically necessary”. The document instead lists formulary controls (tiers, QLs, PA/SP) without explicit not‑medically‑necessary determinations in these segments.

    Some topical product entries state limits such as “Limit 1 Fill per 180 days”, which functionally exclude additional fills beyond the specified maximum; such package/180‑day fill limits should be treated as hard limits for adjudication unless overridden by an approved prior authorization.

    The formulary notes that certain digestive or pancreatic enzyme preparations (e.g., CREON, ZENPEP) list that Non‑FDA approved uses require Prior Authorization. For these enzymes and some large‑unit pancreatic enzyme products, prior authorization is required for uses not included in FDA labeling.

    Consistent with the enzyme entries above, the document reiterates that Non‑FDA approved uses require Prior Authorization — providers must submit a PA when requesting coverage for off‑label enzyme indications.

    As noted earlier, this excerpt does not include explicit “not medically necessary” statements; coverage guidance is expressed via tiers, quantity limits, and PA/SP flags rather than categorical not‑medically‑necessary language.

    Reiterating the previous observations: within these segments there are no explicit not‑medically‑necessary statements; utilization management is implemented through PA, SP, QL, and tier assignments instead.

    This placeholder preserves space for any extended exclusion or coverage text that may be required when the full formulary document is referenced. Consult the full Ambetter formulary for complete product‑level rules and any additional exclusion language.

    Again, in this segment there are no explicit “not medically necessary” declarations; utilization controls (for example, PA and SP) are used to govern access to many high‑cost or specialty agents.

    Codes, Quantity Limits & Examples

    Formulary drug entries (brand/generic, tiers, limits)mixed
    N/ADrug list entries include drug names, tiers, and limits but no CPT/HCPCS/ICD-10 codes in this extract.
    NDC/CPT/HCPCS codesmixed
    No codes listed
    Quantity limit expressionsmixed
    QL(2 EA daily)Quantity limit examples as listed (EA daily)
    QL(1 EA daily)Quantity limit examples as listed (EA daily)
    QL(0.0089 EA daily)Quantity limit example present for RUXIENCE
    NDC/CPT/HCPCS not listed in excerptmixed
    No codes listed
    NDC / drug identifiers and notationsmixed
    not providedDocument lists drug names and formulations but no explicit CPT/HCPCS/NDC codes in this chunk
    No procedural/diagnosis codes in this segmentmixed
    No codes listed
    Opioid new-start limits — key facts for coding and dispensing
    Opioid new-start supply limitNew starts limited to a 7‑day supply; up to two 7‑day fills allowed during any 28‑day period; up to 28 non‑consecutive days in any 90‑day period; fills beyond these limits require Prior Authorization.
    Applies to all opioid formulationsLimit applies cumulatively to all opioid medications filled (documented across formulary entries).
    Provider action for exceptionsFor fills exceeding these limits, providers may submit a Prior Authorization request with justification for extended supply.
    Examples in formulary entriesMultiple opioid and related injectable/solution entries list 'New starts limited to 7 day supply' (e.g., ENBREL entries and hydromorphone/methadone listings).
    Spanish language noteSame 7‑day new‑start policy is shown in Spanish in the formulary ('Nuevos pedidos limitados a suministro de 7 dias').
    Package fill interval — package(s) per 180 days
    Standard package/fill intervalPackage(s) per 180 day(s) — many biologic/adalimumab entries list package limits per 180 days for retail and mail fills.
    Max fills per interval notedSome starter kits and specific presentations include '1 max fill(s) per 180 day(s) retail' or similar package caps.
    Applies to biosimilars and reference biologicsAdalimumab biosimilars and reference products repeatedly indicate package limits per 180 days in Drug Requirements/ILimits fields.
    Document on PA requestsPackage(s) per 180 day(s) retail/mail limits should be documented on prior authorization requests to support coverage/claims adjudication.
    ACTEMRA SOLN per 28 days — retail/mail ML QL values
    ACTEMRA ACTPEN / SOLN per 28 days (retail)QL(3.6 mL per 28 day(s) retail) — ACTEMRA ACTPEN SOLN listing specifies 3.6 mL per 28 days (retail).
    ACTEMRA per 28 days (mail)QL(4 mL per 28 day(s) mail) — ACTEMRA ACTPEN SOLN listing specifies 4 mL per 28 days (mail).
    SP / PA indicatorsACTEMRA ACTPEN entries include specialty (SP) and prior authorization indicators alongside the per‑28‑day QL values.
    Age limits — examples of AL entries
    Example age limit (OTEZLA)AL(At least 45 yrs old Up to 79 yrs old) — OTEZLA tablets and packs specify this age range alongside QL and PA.
    Common topical age minimumAL(At least 12 yrs old) — appears for many topical dermatologic products (e.g., benzoyl peroxide, clindamycin topical).
    Other age minimum examplesAL(At least 2 yrs old) and AL(At least 6 yrs old) appear for select topical or pediatric formulations in the formulary.
    Quantity limits examples — mixed QL examples across document
    Mixed QL examples (EA daily and ML daily)Examples include QL(1 EA daily), QL(4 EA daily), QL(60 EA per fill retail), QL(0.108 ML daily), and QL(1.34 ML daily) shown across entries.
    Cancer therapy QLsAntineoplastic entries show small per‑day QLs (e.g., QL(0.0089 EA daily) for some biologics) and larger EA daily limits for oral oncolytics (e.g., QL(2 EA daily)).
    ML‑based and GM‑based QLsFormulary uses ML (mL) and GM (g) units for solutions and topical formulations (e.g., QL(20 ML daily), QL(3 GM daily)).
    Example quantity limits — sample QL values from formulary
    Sample QL values from formularyExamples include QL(2.47 EA daily) for an ELIQUIS starter pack (with 1 max fill per 180 days); QL(1 EA daily) entries for many antivirals; QL(4 EA daily) for some antiretrovirals; QL(2 EA daily) for TRIZIVIR.
    90‑day and per‑fill limitsSome antiviral/antiretroviral and antiviral agents list per‑fill caps and limits such as 'Limit 1 fill every 90 days' or '50 EA per fill retail/mail'.
    PA / SP context for oncology and specialty agentsMany high‑cost agents list QL plus SP/PA (e.g., RUXIENCE QL(0.0089 EA daily); TRUZIMA/others SP; PA).
    Example QL values — common daily QL examples
    Common daily QL examples (EA)QL(1 EA daily), QL(2 EA daily), QL(3 EA daily), QL(4 EA daily), QL(6 EA daily) — frequent daily limits shown for tablets/capsules across classes.
    Common ML daily examplesQL(20 ML daily), QL(60 ML daily), QL(125 ML per fill retail) — ML limits appear for oral liquids, suspensions, and solutions.
    Topical GM daily examplesQL(1 GM daily), QL(3 GM daily), QL(4 GM daily) — gram‑based daily caps for topical creams/ointments are common.
    Example quantity limits — ml/ea daily QL examples
    ML / EA daily mixed examplesBRIVIACT SOLN PO 10 MG/ML QL(20 ML daily); VALTOCO 15 MG dose QL(60 ML daily); NAYZILAM QL(10 EA per 30 days retail).
    Enoxaparin ML examplesEnoxaparin SOLN IJ 300 MG/3ML QL(6 ML daily); enoxaparin SOSY 100/150 MG/ML QL(2 ML daily); other enoxaparin presentations QL(1.6 ML daily).
    Small‑volume ML daily capsHUMULIN R U‑500 entries show QL(1.34 ML daily) for concentrated insulin solutions.
    Quantity limits examples — assorted QL examples across strengths
    Assorted QL by strength/formulationFluocinonide OINT QL(2 GM daily); Fluticasone propionate CREA 0.05% QL(4 GM daily); Imiquimod 5% QL(12 EA per fill retail/mail); Clindamycin GEL QL(8 ML daily).
    Topical per‑fill capsSome topical creams list per‑fill or per‑30‑day caps (e.g., amcinonide QL 60 GM per fill retail; 1 max fill per 30 days).
    Combination of units and max‑fill rulesEntries combine GM/ML/EA QLs with max fill intervals (e.g., 1 max fill per 180 days for some products).
    Age minimums — common age minimum (≥12 yrs) for several products
    Common age minimum ≥12 yrsAL(At least 12 yrs old) — appears for many topical and systemic products (e.g., benzoyl peroxide, clindamycin topical, prednisone entries).
    Other age minimums presentAL(At least 2 yrs old) for select topical immunomodulators (pimecrolimus); AL(At least 6 yrs old) for certain pediatric formulations appears elsewhere.
    Age limits paired with QL/PAAge minimums are often listed together with QL and PA (claims require supporting age documentation when AL is specified).
    Quantity limits examples — additional QL examples including 90-day and per-fill limits
    90‑day / per‑fill and per‑interval examplesValganciclovir: QL(4 EA daily); Limit fill every 90 days; 10 EA per fill retail/mail. Lamivudine (HBV): Limit 1 fill every QL(125 ML per fill retail); 1 max fill per 90 days.
    Per‑fill maxima for topical/creamsSome topical items list 60 GM per 30 days retail (e.g., isotretinoin) or 90 GM per 1 max fill per 30 days for sulfacetamide products.
    Per‑30‑day ML examplesMetoclopramide SOLN PO QL(60 ML daily) and related ML per‑day/per‑fill limits are used for liquids and suspensions.

    Authorization, Documentation & Risk of Denial

    Prior Authorization

    Prior authorization required — non‑formulary drugs

    Submit a completed Prior Authorization form with all required clinical/supporting information to request coverage for non‑formulary products; Ambetter will respond within 24 hours for urgent requests and within 72 hours for non‑urgent requests. If denied, the notice will state specific reasons or identify missing information needed to complete the request.

    • Use the Ambetter Prior Authorization form and include clinical justification and any requested documentation.
    • Expect urgent request response within 24 hours and non‑urgent within 72 hours (unless state law requires a faster timeline).
    • Denial notices will explain specific reasons or list missing material information.
    Prior Authorization

    PA/SP required for many biologics — document QL and package limits

    Many biologic and specialty agents are designated SP and/or PA and include package or quantity limits (e.g., adalimumab presentations list package(s) per 180 days and QL values); submit prior authorization and observe package/QL limits when requesting coverage.

    • Document package(s) per 180 day(s) and any product QL (e.g., QL(0.143 EA daily) for certain adalimumab presentations).
    • Prior authorization (PA) or specialty pharmacy (SP) routing is required for many biologics — requests missing PA/SP may be denied.
    Documentation Required

    Follow PA/SP flags and QL on formulary entries (e.g., ACTEMRA)

    Formulary entries may include PA and SP flags plus explicit QL values (example: ACTEMRA ACTPEN and SOLN list QL per 28 days and SP/PA indicators); include those flags and QL values on authorization requests.

    • ACTEMRA ACTPEN: QL(3.6 mL per 28 day(s) retail; 4 mL per 28 day(s) mail); SP.
    • ACTEMRA SOLN 200: QL and in some entries a prerequisite 'Must try ibuprofen' (step requirement) — document trials when applicable.
    Prior Authorization

    PA and documentation required for opioid new‑starts (7‑day limit)

    Multiple opioid formulations are subject to prior authorization and have new‑start supply limits; for new opioid starts document indication and adhere to the 7‑day new‑start limit or request PA for supply beyond the limit.

    • New starts limited to a 7‑day supply; prior authorization is required for fills beyond these limits.
    • Document clinical indication and justification when requesting authorization for supply beyond the 7‑day new‑start limit.
    Documentation Required

    Provide age documentation when PA/AL applies

    Some products include age limits (AL) alongside PA (for example OTEZLA lists AL(At least 45 yrs old Up to 79 yrs old)); provide patient age on the PA request and ensure age criteria are met.

    • When an AL is listed, include the patient’s date of birth/age on the authorization to demonstrate eligibility.
    • Claims for patients outside the listed age bounds may be denied if PA and age criteria are not satisfied.
    Prior Authorization

    Submit prior authorization for PA‑designated products

    Any product listing 'PA' in its Drug Requirements/Limits field requires prior authorization before coverage; providers must submit PA for those formulations (examples appear throughout the formulary).

    • Check the Drug Requirements/Limits field for 'PA' or 'SP; PA' and submit authorization accordingly.
    • Failure to submit PA for PA‑designated presentations may result in claim denial.
    Prior Authorization

    Confirm PA for listed product presentations (e.g., enoxaparin)

    Multiple listed products (including enoxaparin presentations) include 'PA' — verify PA requirement for the exact presentation and submit authorization with the product’s QL/package info.

    • Examples: enoxaparin sodium presentations list QL values and PA; include the specific formulation and QL in the PA request.
    • Record package‑per‑180‑days limits where present.
    Prior Authorization

    PA required for select branded formulations (e.g., TRIJARDY XR, REZVOGLAR)

    Certain branded and combination products (examples include TRIJARDY XR, REZVOGLAR KWIKPEN and others) are subject to prior authorization — include the product and NPI/prescriber details on the PA submission.

    • TRIJARDY XR entries show QL and PA indicators — submit PA when requesting coverage.
    • REZVOGLAR KWIKPEN is listed with ILimits = PA; include required documentation when submitting.
    Prior Authorization

    PA required for select antifungal and other agents (e.g., itraconazole CAPS)

    Some specific agents are marked 'PA' in the formulary (example: itraconazole CAPS); submit prior authorization with clinical rationale for these select products.

    • Itraconazole CAPS: ILimits = ... PA — include indication and dosing on the PA form.
    • Other antifungals may have QL and PA; verify each formulation’s entry.
    Billing Rule

    Specialty pharmacy (SP) and prior authorization required for many formulary drugs

    Numerous formulary drugs include PA and/or SP flags; when a product is listed with 'SP' or 'SP; PA' route fulfillment through the specialty network and submit PA documentation as required.

    • Examples: oncology/immunomodulators and many specialty injectables list SP; PA — coordinate specialty pharmacy routing.
    • Include QL, package limits and clinical justification in the PA to avoid delays or denial.
    Documentation Required

    Provide PA documentation for products labeled 'PA' or 'SP; PA'

    Drugs explicitly labeled 'PA' or 'SP; PA' require prior authorization; providers must supply documentation consistent with those requirements to prevent coverage denials.

    • Examples: PERSERIS PRSY shows QL(...)/PA; FUZEON SOLR shows SP; PA — include required clinic notes and specialty routing info.
    • Claims without PA/SP for these entries may be denied.
    Prior Authorization

    PA required for select cardiac and pulmonary hypertension agents

    Certain cardiac and pulmonary hypertension agents and strengths (e.g., verapamil CP24 strengths; TYVASO/treprostinil kits and solutions) are PA or SP; submit PA and specialty documentation when requesting these therapies.

    • Verapamil CP24 100/200/300 MG: Drug RRequirements/ILimits = PA — include indication on PA.
    • TYVASO starter/refill kits and treprostinil SOLN IJ: ILimits include QL and PA; route via specialty as indicated.
    Documentation Required

    PA required for select topical agents — document age and indication

    Certain topical clindamycin formulations and combination topical acne products list PA and age limits; submit PA and document patient age and quantity needs for coverage.

    • Clindamycin phosphate topical FOAM: AL(At least 12 yrs old); PA — include DOB and indication.
    • Clindamycin–benzoyl peroxide combinations: AL(At least 12 yrs old); PA — include prior topical therapy/step info if applicable.
    Prior Authorization

    Submit PA for topical products where 'PA' is listed

    Multiple topical agents across the formulary show 'PA' in the Drug Requirements/Limits field; providers must submit prior authorization when PA is indicated for the topical formulation requested.

    • Examples include clindamycin phosphate–benzoyl peroxide gel and luliconazole which list PA — attach relevant clinical notes to the PA.
    • Where QL or max fills per interval appear, include supply requested and justification.
    Prior Authorization

    Prior authorization required when 'PA' is shown in formulary entry

    Products with 'PA' in their Drug Requirements/Limits require prior authorization; providers must submit PA before dispensing to obtain coverage for those items.

    • Review the Drug Requirements/Limits field for 'PA' on each product presentation before claim submission.
    • Attach product‑specific clinical documentation to the PA to demonstrate medical necessity.
    Prior Authorization

    PA required for non‑FDA uses and select products (document indication)

    Prior authorization is required for certain non‑FDA uses and specified products (examples: FOSAMAX PLUS D, some risedronate and large‑unit enzyme products); submit PA with documentation of the non‑FDA indication and rationale.

    • Non‑FDA approved uses explicitly state 'Non‑FDA approved uses require Prior Authorization' — include supporting clinical rationale.
    • Example: FOSAMAX PLUS D ILimits = ... PA — include indication and prior therapy when requesting PA.
    Step Therapy

    Comply with Step Therapy requirements — document prior trials

    Step Therapy (ST) requires members to try specified drugs before Ambetter will cover an alternative; where an entry includes 'ST' or a 'Must try' note (e.g., ACTEMRA), document prior trials on the authorization.

    • When 'ST' or a 'Must try' requirement appears, include evidence of trial and failure/intolerance of preferred agent(s).
    • If step requirements are not met, coverage may be denied until criteria are satisfied.
    Step Therapy

    Observe ST/SP flags — try preferred agents or use specialty routing as indicated

    Some formulary entries include 'SP' or 'Must try' phrasing suggesting step or specialty program controls (examples include ACTEMRA and other high‑tier agents); follow the listed ST/SP indicators when submitting requests.

    • If 'SP' is listed, arrange fulfillment via Ambetter’s specialty pharmacy network and include specialty routing details on PA.
    • If a 'Must try' preferred agent is listed, document the trial on the prior authorization.
    Note

    Tiering may imply step access — confirm ST where present

    Where step therapy sequences are not explicitly described in this excerpt, tier assignments imply preferred access but specific step requirements must be confirmed from the formulary entry and documented on PA when 'ST' is shown.

    • Tiering (1A/1B/2/3/4) implies preferred access; check the specific Drug Requirements/Limits for ST language.
    • If ST is flagged, document prior attempted therapies per the formulary requirement.
    Documentation Required

    Document QL and package‑per‑180‑day values on PA requests

    When submitting a prior authorization, include product QL/package values and any relevant package per 180‑day limits so adjudicators can validate the requested supply against formulary limits.

    • Record package(s) per 180 day(s) retail/mail limits and specific QL (e.g., ACTEMRA QL per 28 days, adalimumab package per 180 days) on the PA form.
    • Claims or PA requests that do not document package/QL values may be subject to denial or delay.
    Documentation Required

    Document justification for opioid new‑start supply beyond 7 days

    Document supply justification for new‑start opioid fills when requesting PA — new starts are limited to a 7‑day supply and prescribers should state the indication and reason for any supply beyond 7 days.

    • For new opioid prescriptions, indicate the clinical reason for more than a 7‑day supply if requesting PA.
    • Include prior analgesic history and any prior authorization rationale in the request.
    Billing Rule

    Include formulary QL/PA values on claims and PA submissions

    Use the formulary’s listed QL and PA values when completing pharmacy claims and PA submissions — entries such as ELIQUIS starter packs, naloxone limits, and biologic QLs must be reflected in the request.

    • ELIQUIS STARTER PACK: QL and max fill per 180 days must be included when requesting coverage.
    • Naloxone entries include QL and max fills per interval — document these when submitting PA or processing claims.
    Documentation Required

    Attach required clinical documentation for PA/SP drugs

    Provide clinical documentation consistent with PA requirements for drugs marked 'PA' or 'SP' (lack of necessary documentation increases risk of denial).

    • Attach clinical notes, prior therapy history, labs or other required evidence to support medical necessity.
    • For SP agents, include specialty pharmacy routing and any enrollment information required by the specialty program.
    Documentation Required

    Include patient age/DOB for age‑limited products

    When age limits (AL) apply (e.g., pimecrolimus AL(At least 2 yrs old); OTEZLA AL(At least 45 yrs old Up to 79 yrs old)), include patient age/DOB on the authorization to demonstrate eligibility.

    • Claims or PA requests missing patient age evidence for AL‑restricted products may be denied.
    • Document both minimum and maximum age criteria where listed.
    Documentation Required

    Record product QL and AL values on PA requests and claims

    Document quantity limits (QL) and age limits (AL) per product on PA requests and claims; many products (including injectables, topical and specialty agents) specify QL values that are used in adjudication.

    • Examples: TYVASO STARTER KIT: QL(3 EA daily); clindamycin toppicals: QL( GM daily); naloxone SOLN: QL(4 EA daily) with max fills — include these values on requests.
    • Exceeding QL or failing to provide justification may lead to denial.
    Denial Risk

    If PA denied — notice will state reasons or missing information

    If a prior authorization request is disapproved, the denial will explain the specific reasons or identify missing material information needed to complete the request; use that guidance to correct and resubmit if appropriate.

    • Review denial notice for explicit reasons or missing documentation and provide the identified material information if resubmitting.
    • Timely responses to deficiency notices may affect reconsideration timelines.
    Denial Risk

    Denial risk — requests exceeding package/180‑day or QL

    Requests that exceed package(s) per 180 days or exceed listed quantity limits (QL) are at risk of prior authorization denial; verify package/QL limits before submitting a request for additional supply.

    • Adalimumab and some antifungal/topical entries list package or max‑fill per 180 days — exceeding those will risk denial.
    • Include justification and clinical rationale if requesting exceptions to package or QL limits.
    Denial Risk

    Denial risk for biologics without PA/SP and required QL

    Biologic entries that list 'SP' or 'PA' plus specific QL values (e.g., RUXIENCE, TRUXIMA, COSENTYX, ADALIMUMAB presentations) may be denied if PA/SP requirements or QL restrictions are not met.

    • RUXIENCE: ILimits = PA; QL(0.0089 EA daily); SP indicated — supply requests without PA/SP documentation risk denial.
    • COSENTYX and other biologics list QL and PA — include QL and specialty routing on PA.
    Denial Risk

    Denial risk when PA and age limits are not met

    Claims for products listed with both PA and age limits may be denied if PA is not obtained or the patient’s age does not meet the AL specified on the formulary entry.

    • OTEZLA entries include AL(At least 45 yrs old Up to 79 yrs old) plus PA — ensure both PA and age compliance.
    • Provide DOB/age in PA to avoid age‑related denials.
    Denial Risk

    Denial risk — claims missing PA for PA‑designated presentations

    Products explicitly listed with 'PA' (for example amiodarone SOLN, enoxaparin presentations) indicate prior authorization is required; claims lacking PA for these PA‑designated presentations may be denied.

    • Amiodarone hcl SOLN: ILimits = PA — include PA prior to claim submission.
    • Enoxaparin SOSY / SOLN presentations list PA and QL — ensure PA is obtained where required.
    Denial Risk

    Denial risk — exceeding specified QL without justification

    Exceeding a product’s specified quantity limit (QL) without appropriate justification or override is a common cause for denial; check the QL field and attach justification if an exception is requested.

    • Examples include enoxaparin QL per day values and multiple topical QLs — requests beyond these values require PA with rationale.
    • PA requests should reference the exact QL expression from the formulary entry.
    Denial Risk

    Denial risk when QL, SP or PA requirements are incomplete

    Entries that combine QL with SP and PA (format 'QL(...); SP; PA') indicate both quantity and specialty/prior authorization controls; failure to satisfy any of these requirements can cause denial.

    • For products showing 'QL(...); SP; PA' include QL, specialty routing, and PA documentation in the submission.
    • Claims lacking any required element (QL justification, PA, or SP routing) are subject to denial.
    Denial Risk

    Denial risk if step‑therapy (ST) trials are not documented

    When a formulary entry shows 'ST' (step therapy) the plan requires a prior trial of preferred therapy before covering the requested drug; failure to document required prior trials may result in denial.

    • Bromocriptine mesylate CAPS lists 'ST' — document the required prior therapy trial on the PA.
    • Some topical combination entries also show ST; include prior trial evidence where applicable.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    New-Start & Initial Therapy Requirements

    New start limits

    New start limitations noted

    New start supply limits: Multiple products (including many injectable biologics and opioid-related formulations) note 'New starts limited to 7 day supply'; prior authorization is required for supply beyond this initial 7‑day limit.7‑day supply

    Applies where the product entry explicitly states 'New starts limited to 7 day supply'.

    Initial therapy notes

    Some topical agents require step therapy before advanced agents.

    Step/PA noted for topical agents: Certain topical combination products are flagged with ST (step therapy) or PA; when ST is present a trial of the preferred/earlier‑line product is required prior to coverage of the higher‑tier or combination formulation. Exact step sequencing is not provided in this excerpt.

    Examples include clindamycin–tretinoin and other topical combinations listed with ST/PA.

    Step Therapy Flags & Mappings

    ProductFormulary TierDrug Requirements / Limits
    lisdexamfetamine dimesylate CAPS
    Tier = 1B
    QL( T EA daily); ST
    ProductFormulary TierDrug Requirements / Limits
    ACTEMRA SOLN 200
    Tier = 1B
    Must try ibuprofen; QL(5 EA daily)
    ProductFormulary Tier / FlagDrug Requirements / Limits
    vigabatrin PACK / TABS
    Tier = (listed); ST/SP flag present
    QL(6 EA daily); PA noted in nearby entries for similar agents
    Product or GroupTier AssignmentNotes
    Various branded and combination antidiabetics (e.g., TRIJARDY XR, SYNJARDY XR)
    Tiers shown (examples include Tier = 1A, 1B, 2, 3, 4)
    Explicit step sequences or required prior trial failures are not provided in the excerpt
    ProductFormulary TierDrug Requirements / Limits
    amlodipine-valsartan-hydrochlorothiazide (combination)
    Tier = 1B (example)
    ST indicated in Drug Requirements/ILimits
    ProductFormulary Tier / FlagDrug Requirements / Limits
    antiparkinson agents (example: carbidopa-levodopa formulations)
    Tier = 1B (examples shown)
    ST flags present for some antiparkinson agents; specific step rules not shown
    ProductFormulary Tier / FlagDrug Requirements / Limits
    bromocriptine mesylate CAPS
    Tier (listed)
    Drug RRequirements/ILimits = ST
    ProductDesignationDrug Requirements / Limits
    treprostinil SOLN IJ
    Tier = 4; SP indicated
    ILimits = SP; PA
    Topical ProductFormulary Tier / DesignationDrug Requirements / Limits
    clindamycin phosphate (topical) FOAM / GEL / LOTN
    Tier = 1B
    AL(At least 12 yrs old); some forms list PA; QL values shown (e.g., QL( GM daily); QL(8 ML daily))
    Topical ProductFormulary Tier / FlagDrug Requirements / Limits
    amcinonide (cream/lotn/oint)
    Tier = 1B (examples)
    ILimits include ST and QL (e.g., QL(60 GM per fill retail)); PA noted for some topical entries
    Product / Mappingprug Name (Preferred alternative)Implication
    fluticasone propionate CREA 0.05%
    prug Name = triamcinolone acetonide OINT 0.5%
    Indicates a preferred alternative mapping; may imply trial of preferred product/class before non-preferred coverage
    ProductDesignationDrug Requirements / Limits
    pamidronate disodium SOLN 30 MG/10ML
    Designation = SP; PA
    ILimits = SP; PA (specialty + prior authorization required)

    Quantity Limits (QL) — Examples by Product

    ADHD & stimulant QLs — multiple stimulant products with daily and per-fill QLs
    Multiple stimulant products QLsExamples include QL(1 EA daily), QL(2 EA daily), QL(6 EA daily), and QL(280 ML per 56 day(s) retail/mail) across methylphenidate, amphetamine, lisdexamfetamine and modafinil listings.
    Patch and chewable formatsMethylphenidate patch and chewable forms show QL(1 EA daily) or QL(2 EA daily) depending on presentation and age limits.
    Step therapy and PA flagsSome stimulant/lisdexamfetamine entries include ST (step therapy) or PA in addition to QL (e.g., lisdexamfetamine entries list QL plus ST).
    Opioids (new starts) QL summary — 7-day new-start limits and refill cadence
    7‑day new‑start cap and refill cadenceNew starts limited to a 7‑day supply; up to two 7‑day fills in any 28‑day period; up to 28 non‑consecutive days in any 90‑day period — fills beyond require PA.
    Applied across opioid entriesNumerous opioid presentations (oral, solution, injectable) are marked with 'New starts limited to 7 day supply' in their ILimits fields.
    Provider documentation requirementPrescribers should document indication and justification when requesting PA for supply exceeding the new‑start limits.
    Adalimumab products QL/package limits — package(s) per 180 days and QL examples
    Adalimumab package and QL examplesAdalimumab presentations list package(s) per 180 day(s) (retail/mail) and QL examples such as QL(0.143 EA daily) or QL(0.0143 ML daily); PA is indicated.
    Starter kits and max fillsSome adalimumab starter kits include '1 max fill(s) per 180 day(s) retail' in addition to package limits and PA.
    Biosimilars treated similarlyMultiple adalimumab biosimilars and reference HUMIRA are listed with analogous package/QL/PA constraints across entries.
    ACTEMRA ACTPEN QL per 28 days — ML per 28 days retail/mail values
    ACTEMRA ACTPEN per 28 days retail/mailQL(3.6 ML per 28 day(s) retail; 4 ML per 28 day(s) mail) — ACTEMRA ACTPEN SOLN listing specifies these ML QLs for retail and mail.
    SP indicator presentACTEMRA ACTPEN entries include 'SP' (specialty) flags alongside the per‑28‑day QL values for some presentations.
    ACTEMRA SOLN strength notesSome ACTEMRA SOLN presentations list different QLs (e.g., QL(40 ML per 28 days) in other formulations); check the specific entry when coding/dispensing.
    OTEZLA TABS QL — QL(2 EA daily)
    OTEZLA tablets QLQL(2 EA daily) — OTEZLA tablets list a daily quantity limit of 2 each.
    NSAID examples QL — oxaprozin/piroxicam/sulindac examples
    NSAID example QLsoxaprozin, piroxicam, sulindac entries include QL examples (e.g., QL(6 EA daily) for some NSAIDs).
    Fluticasone propionate HFA QLsFluticasone propionate HFA listed with QL(4 ML daily) for HFA formulations (and GM‑based QLs for creams).
    Formulation‑dependent limitsQuantity limits vary by formulation (tablet vs inhaler vs topical) — use the exact product line when applying the QL.
    ENBREL formulations QL — ML-based QL differences by formulation
    ENBREL formulation QLs (ML) vs EAENBREL SOLN entries show 'New starts limited to 7 day' and QL examples such as QL(0.146 ML daily) or QL(0.286 ML daily) depending on presentation; some presentations also list QL(4 EA daily) with PA.
    SP/PA present for higher‑concentration formsHigher‑concentration ENBREL SOSY 50 MG/ML lists SP; PA alongside ML‑based QLs.
    Dispensing noteObserve both ML and EA QLs when coding or dispensing different ENBREL presentations to ensure claim compliance.
    Buprenorphine formulations QL — film/sub-lingual QL examples
    Buprenorphine formulation QLsBuprenorphine films/sub‑lingual formulations show QL(3 EA daily) for some film/tablet presentations and QL(180 ML daily) for certain solution presentations.
    Combination products referenceButalbital‑aspirin/caffeine/codeine listings reference buprenorphine/naloxone products as related formulations in prug Name fields while indicating QLs and 7‑day new‑start limits for opioid‑containing combos.
    PA flags may applySome buprenorphine presentations include PA alongside QL depending on formulation and strength.
    Budesonide (intrarectal) QL — QL(3.2 GM)
    Budesonide (intrarectal) QLQL(3.2 GM) — budesonide intrarectal listing shows a 3.2 gram QL.
    Hydrocortisone acetate (rectal) QLQL(4 EA daily) — hydrocortisone acetate (rectal) entries list a 4 each per day QL.
    Nitroglycerin (intra‑anal) QLQL(2 GM daily) — nitroglycerin intra‑anal listing uses gram‑based daily QL.
    Hydrocortisone acetate (rectal) QL — QL(4 EA daily)
    Hydrocortisone acetate (rectal) QLQL(4 EA daily) — rectal hydrocortisone acetate entries list 4 each daily.
    Nitroglycerin intra‑anal QLQL(2 GM daily) — intra‑anal nitroglycerin entries specify 2 grams per day.
    Lidocaine SOLN QLQL(10 ML) — lidocaine HCl solution lists a 10 mL per fill/period QL in the formulary.
    Alprazolam QL examples — QL(4 EA daily) for multiple strengths
    Alprazolam daily QL examplesQL(4 EA daily) — alprazolam tablets (0.25–1 mg and 2 mg strengths) are listed with a 4 each per day limit.
    Alprazolam ML exampleSome alprazolam presentations (liquid/other forms) show ML‑based QLs such as QL(0.036 ML daily) for specific formulations.
    Implication for dispensingApply the per‑day EA QL when dispensing tablet forms; check ILimits for non‑tablet forms that may use ML QLs and PA requirements.
    Alprazolam 2 mg QL — QL(4 EA daily)
    Alprazolam 2 mg QLQL(4 EA daily) — alprazolam 2 mg tablets are listed with a 4 each per day limit.
    Tiotropium/inhaler QL — QL(1 EA daily)
    Tiotropium/inhaler QLQL(1 EA daily) — tiotropium bromide inhaler presentations list one each per day as the quantity limit.
    Inhaler formulation noteInhaled products commonly use EA daily QLs (one device per day) — verify specific inhaler entry when coding or dispensing.
    Fluticasone propionate HFA QL — QL examples by formulation (GM/ML)
    Fluticasone propionate HFA / formulation QLsFluticasone propionate HFA listed with QL(4 ML daily) for some HFA inhaler solutions and QL(0.8 GM daily) or GM/ML distinctions depending on formulation.
    Topical vs inhaled differencesSame active ingredient may have GM‑based QLs for topical forms and ML‑based QLs for HFA/inhalation forms — use the specific product line when applying limits.
    Check ILimits field for exact unitsFormulary entries include the unit (GM/ML/EA) in ILimits — important when documenting PA or claims.
    ELIQUIS starter pack QL — QL(2.47 EA daily); 1 max fill per 180 days retail
    ELIQUIS starter pack QL and max fillQL(2.47 EA daily) for ELIQUIS starter pack; 1 max fill(s) per 180 days (retail) is specified for the starter presentation.
    SP indicatorELIQUIS starter pack entry includes SP routing for some presentations in ILimits fields.
    Rivaroxaban suspension QL — QL(900 ML per 30 days retail)
    Rivaroxaban suspension QLQL(900 ML per 30 day(s) retail) — rivaroxaban suspension listings specify 900 mL per 30 days for retail and mail presentations.
    Concentrated liquid examplesLarge ML per 30‑day limits are used for some suspensions/solutions — verify the exact ML value in the ILimits field when coding.
    Enoxaparin SOLN IJ QL — QL(6 ML daily)
    Enoxaparin SOLN IJ QL examplesenoxaparin sodium SOLN IJ 300 MG/3ML: QL(6 ML daily) — listed in ILimits for this presentation.
    Enoxaparin SOSY examplesenoxaparin SOSY 100 MG/ML, 150 MG/ML: QL(2 ML daily); enoxaparin SOSY 80 MG/0.8ML, 120 MG/0.8ML: QL(1.6 ML daily).
    Formulation‑dependent ML dosingDifferent enoxaparin concentrations/presentations use different ML daily QLs — dispense using the specific presentation's ML QL.
    XARELTO 15 MG QL — 2 EA daily
    XARELTO 15 mg QLQL(2 EA daily) — XARELTO tablets 15 mg are listed with a 2 each per day limit.
    Enoxaparin SOSY QL examples — 2 ML daily and 1.6 ML daily depending on presentation
    Enoxaparin SOSY varying QLsenoxaparin SOSY 100/150 MG/ML: QL(2 ML daily); enoxaparin SOSY 80/0.8ML & 120/0.8ML: QL(1.6 ML daily) — QLs depend on concentration/presentation.
    Some entries include PACertain enoxaparin presentations list PA alongside the QL in the ILimits field.
    NAYZILAM & VALTOCO & BRIVIACT examples — assorted ML/EA daily limits
    NAYZILAM and VALTOCO QLsNAYZILAM: QL(10 EA per 30 days retail); VALTOCO 15 mg dose: QL(60 ML daily) — both entries include QLs and PA or ST flags.
    BRIVIACT solution QLBRIVIACT SOLN PO 10 MG/ML: QL(20 ML daily); PA indicated for solution form.
    Assorted EA/ML examples for epilepsy agentsCarbamazepine, vigabatrin, and others list mixed EA daily QLs (e.g., 3 EA, 6 EA, 4 EA daily) depending on formulation/strength.
    BRIVIACT SOLN QL — 20 ML daily
    BRIVIACT SOLN QLQL(20 ML daily) — BRIVIACT solution (10 mg/mL) lists a 20 mL per day limit in ILimits.
    Epilepsy product examples — vigabatrin, SPRAVATO QL/PA examples
    Epilepsy product QLs and PA examplesVigabatrin PACK/TABS: QL(6 EA daily); SPRAVATO (84 mg dose): PA and in some entries QL(1 EA daily).
    BRIVIACT and other agentsBRIVIACT SOLN PO QL(20 ML daily) and other anticonvulsants list varied QLs and PA/ST where indicated.
    Mixed QL examples summary — aggregated examples like QL(1 EA daily), QL(4 EA daily), ml-based QLs
    Mixed aggregated QL examplesCommon aggregated examples include QL(1 EA daily), QL(4 EA daily), QL(8 EA daily), ML‑based QLs (e.g., QL(0.108 ML daily), QL(1.34 ML daily)), and GM‑based topical QLs.
    Unit diversity in QLsFormulary expresses limits in EA (each), ML (mL), and GM (g) depending on product type — always reference the product ILimits unit.
    Claims/PA implicationExceeding the listed QL without PA or override may result in denial; document QL/PA on requests as specified in entries.
    Naloxone retail limits — naloxone hcl LIQD retail limit examples and max fills
    Naloxone retail/liquid limitsNaloxone HCl solution: QL(4 EA daily); 3 max fills per 365 days (retail & mail) and PA for some presentations; retail limits and max fills specified in ILimits.
    Provider documentation for naloxoneFormulary entries advise documenting QL/PA on PA requests or claims for naloxone liquid/solution presentations.
    Naloxone presence across formulationsMultiple naloxone presentations (liquid, solution) include QLs and max‑fill caps in ILimits fields — check specific product line when dispensing.
    Ondansetron QLs — 4 mg and 8 mg tab per-day and per-fill limits
    Ondansetron QL (4 mg tabs)QL(4 EA daily; 60 EA per fill retail; 60 per fill mail) — ondansetron 4 mg tablet listing specifies daily and per‑fill caps.
    Ondansetron QL (8 mg tabs)QL(3 EA daily; 45 EA per fill retail; 45 per fill mail) — ondansetron 8 mg tablet listing specifies slightly lower daily and per‑fill caps.
    Per‑fill parity retail/mailPer‑fill limits are specified for both retail and mail for ondansetron 4 mg and 8 mg tablets — apply the correct per‑fill cap by channel.
    Fenofibrate & cetirizine QLs — QL(1 EA daily) examples
    Fenofibrate QL exampleFenofibrate micronized (67/134/200 mg): QL(1 EA daily) — common daily tablet QL for fibrates.
    Cetirizine QL exampleCetirizine HCl tablets: QL(1 EA daily) — typical daily OTC antihistamine QL in formulary.
    Clonidine QL — QL(0.15 EA daily) example
    Clonidine topical QL exampleClonidine PTWK: QL(0.15 EA daily) — clonidine transdermal patch listing includes a 0.15 each per day QL example.
    Oncology/immunology QLs — RUXIENCE, TAGRISSO, ALECENSA, ZELBORAF examples
    Oncology/immunology QL examplesRUXIENCE: QL(0.0089 EA daily); TAGRISSO 40 mg: QL(2 EA daily); ALECENSA: QL(8 EA daily); ZELBORAF: QL(8 EA daily) — oncology/immunology agents include small EA‑per‑day QLs and SP/PA flags.
    SP/PA frequentMany antineoplastic agents are listed with SP and PA in ILimits, indicating specialty routing and prior authorization requirements.
    Dose‑dependent QLsDifferent strengths of the same antineoplastic may have different QLs (verify the exact strength entry).
    Psychiatric injectable QL examples — haloperidol decanoate/clozapine examples
    Psychiatric injectable QLsHaloperidol decanoate: QL(0.036 ML daily); Clozapine TBDP 100 mg: QL(9 EA daily) — examples of injectable/long‑acting psychiatric QLs.
    PA/ST flags sometimes presentSome long‑acting psychiatric injectables include PA or SP in ILimits; check the specific product line for prior authorization requirements.
    TRIZIVIR & valganciclovir QL examples and per-fill/90-day limits
    TRIZIVIR & valganciclovir QLs and fill limitsTRIZIVIR: QL(2 EA daily); 50 EA per fill retail/mail. Valganciclovir HCl tabs: QL(4 EA daily); Limit fill every 90 days; 10 EA per fill retail/mail.
    Per‑90‑day restrictionsSome antiviral agents require limited fills every 90 days with per‑fill caps (documented in ILimits).
    Implication for dispensingAdhere to per‑fill and interval limits (90‑day) to avoid PA denial or claim rejection.
    Lamivudine HBV & SOLU-CORTEF examples — per-fill, per-90-day limits
    Lamivudine (HBV) per‑fill limitLimit 1 fill every QL(125 ML per fill retail); 1 max fill(s) per 90 days — lamivudine (HBV) entry includes a 125 mL per‑fill cap with a 90‑day max fill interval.
    Desmopressin QLsDesmopressin SOLN NA: QL(6 EA daily); Desmopressin tabs: QL(6–8 EA daily) — listed across desmopressin presentations.
    Specialty/PA flagsSome of these antiviral and specialty entries include PA/SP indicators that affect dispensing and authorization workflows.
    TYVASO and pulmonary HTN product QLs — TYVASO starter kit QL example
    TYVASO starter kit QLTYVASO STARTER KIT SOLN IN: QL(3 EA daily); PA — the starter kit lists a 3 each per day QL with PA for the starter/refill kits.
    Treprostinil and pulmonary HTN agentsTreprostinil SOLN IJ: SP; PA — prostacyclin agents and pulmonary hypertension therapies frequently require SP and PA with specified QLs.
    Route/site‑of‑care implicationThese products often require specialty pharmacy or infusion center handling and PA documentation for coverage.
    Injectable contraceptive JQL example — norethindrone/ethinyl estradiol injectables JQL per 90 days
    Injectable contraceptive JQLJQL(1 ML per 90 day(s) retail) — norethindrone acetate/ethinyl estradiol injectables list a JQL of 1 mL per 90 days (retail).
    Documentation noteUse the JQL value when documenting quantity limits for injectable contraceptives on PA requests or claims.
    Topical agents QLs — clindamycin, benzoyl peroxide, pimecrolimus, fluocinonide examples
    Topical agents QL examplesClindamycin topical forms: QL(3 GM daily) or QL(8 ML daily); Benzoyl peroxide: QL(3 GM daily); Pimecrolimus: QL(3 GM daily); Imiquimod 5%: QL(12 EA per fill retail/mail).
    Unit diversity for topicalsTopical QLs use GM (grams), ML (mL), or EA (each) per fill/day depending on formulation — confirm units on the product line.
    Max‑fill and age interactionsSome topical products combine QL with AL (age minimums) and per‑fill or per‑interval max fills that affect dispensing frequency.
    Lidocaine & imiquimod QLs — lidocaine SOLN QL(10 ML); imiquimod per-fill limits
    Lidocaine & imiquimod QLsLidocaine HCl Solution: QL(10 ML) per fill/period; Imiquimod 5%: QL(12 EA per fill retail; 12 per fill mail).
    Lidocaine patch PA noteLidocaine patch 5% listed with PA for certain presentations; solution lists the 10 mL QL and max fill intervals.
    Oral diuretics & antihypertensives QLs — triamterene, DIURIL, HCTZ examples
    Oral diuretics & antihypertensives QLsExamples: DIURIL SUSP QL(20 ML daily); Hydrochlorothiazide TABS/CAPS QL(2 EA daily); Acetazolamide TABS 250 mg QL(4 EA daily).
    Combination diuretic QL examplesTriamterene & hydrochlorothiazide CAPS 25/37.5 mg list per‑day QLs in ILimits (e.g., T EA daily).
    Claims/dispensing implicationAdhere to daily EA/ML QLs for diuretics at dispensing and when calculating days supply for claims.
    Acetazolamide & other QLs — acetazolamide QL(4 EA daily)
    Acetazolamide QLAcetazolamide TABS 250 mg: QL(4 EA daily) — documented in ILimits for multiple acetazolamide presentations.
    Desmopressin QLsDesmopressin SOLN: QL(6 EA daily); Desmopressin tabs: QL(6–8 EA daily) depending on tablet strength and presentation.
    Implication for chronic therapyChronic use QLs for these agents should be checked per‑product (some forms may have SP/PA or unit‑based QLs).
    Combination diuretic/triamterene QLs — combination product QL examples
    Combination diuretic/triamterene QL exampleTriamterene & hydrochlorothiazide CAPS 25 mg‑37.5 mg: ILimits indicate per‑day EA QL (e.g., 'T EA daily') — confirm specific numeric QL on product line.
    Hydrochlorothiazide QLHydrochlorothiazide CAPS/TABS: QL(2 EA daily) — standard daily tablet QL across many strengths.
    Bisphosphonate QLs — ibandronate, risedronate QL examples
    Bisphosphonate QL examplesIbandronate TABS: QL(0.036 EA daily); Risedronate 150 mg: QL(0.036 EA daily); FOSAMAX PLUS D: QL(0.143 EA daily) with PA for some presentations.
    PA/SP for some formulationsCertain bisphosphonate presentations may include PA or SP flags in ILimits, affecting dispensing and coverage.
    Desmopressin QLs — soln/tabs examples
    Desmopressin SOLN and tabs QLsDesmopressin SOLN NA: QL(6 EA daily); Desmopressin tabs 0.1 mg: QL(6 EA daily); tabs 0.2 mg: QL(8 EA daily).
    PA flag for some formsDesmopressin entries also note PA for selected presentations; check ILimits for PA requirements.
    Lubiprostone QL — QL(2 EA daily)
    Lubiprostone QLQL(2 EA daily) — lubiprostone entries specify a 2 each per day limit.
    Daily ML examples for GI liquidsSome GI stimulant/solution entries show ML‑based daily QLs (e.g., QL(0.72 ML daily) for related agents).

    Specialty Pharmacy, Infusion & Site Requirements

    Note

    Route SP‑designated drugs through Ambetter specialty/hemophilia pharmacies

    Specialty drugs listed with 'SP' often require fulfillment at a pharmacy within Ambetter’s specialty or hemophilia network; providers must arrange dispensing through the required specialty network when SP is indicated.

    • Confirm specialty pharmacy network routing when SP is shown
    • Coordinate PA and specialty fulfillment to avoid delays
    Note
    Note
    Billing Rule

    Secure PA and coordinate infusion/Specialty handling for IV/infusion agents

    IV/infusion oncology and select infusion agents flagged with PA/SP (e.g., treprostinil SOLN IJ, TYVASO kits) imply infusion‑center handling; providers should secure PA and schedule fulfillment at an appropriate infusion site or specialty pharmacy as required.

    • Obtain PA and confirm SP handling or infusion‑center scheduling for IV/infusion agents
    • Include QL and kit information (e.g., TYVASO QL(3 EA daily)) in the PA

    Biosimilar & Reference Product Notes

    Prior Authorization

    Include QL/package and PA when requesting adalimumab/biosimilar coverage

    Adalimumab reference and biosimilar presentations are listed with QL and PA indicators and package limits per 180 days; providers must include the adalimumab presentation, package/QL details, and PA request when seeking coverage.

    • Include package(s) per 180 day(s) and QL values (e.g., QL(0.143 EA daily)) in the PA
    • Obtain PA prior to dispensing adalimumab reference or biosimilar presentations

    Abbreviations & Terms

    Definitions — PA, ST, QL (key utilization terms)
    PA = Prior AuthorizationPA (Prior Authorization) — provider must request approval from Ambetter before some drugs will be covered; used throughout the formulary entries.
    ST = Step TherapyST (Step Therapy) — members may be required to try specified drugs first before Ambetter covers alternatives; appears as 'ST' in ILimits fields.
    QL = Quantity LimitQL (Quantity Limit) — maximum quantity allowed in a specified time period and expressed with units (EA, ML, GM) in ILimits fields.

    Policy Background & Scope

    Background: The formulary lists FDA‑approved brand and generic medications covered under the prescription drug benefit. Generics are presented as first‑line options when available; preferred brand drugs are identified (e.g., Tier 2) when a generic is not suitable.